JD Supra: Mergers

MARCH 31, 2025

Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies. By: Goodwin

Securities 183

Securities Pharmaceutical Medical Public Trading 183

OfficeHours

JULY 18, 2023

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) For example, relevant platforms in this space include AmeriVet (owned by AEA and ADIA) and VetCor (owned by Oak Hill).

Private Equity 130

Private Equity Equities Investment Mergers and Acquisitions 130

Cooley M&A

OCTOBER 19, 2022

Notable public deals. Amazon to Acquire One Medical for $3.9 Lavoro to Become Publicly Traded Through Business Combination With TPB Acquisition Corporation I. Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Sixth Street Invests in Blueprint Medicines. Awards, recognition and accolades.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Focus Investment Banking

JUNE 13, 2023

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. Formerly owned by Tahoe Investment Group, which bought the company in April 2017, Alliance was acquired by Akumin, a publicly traded company, in June 2021 for $820 million.

Hospitality 52

Hospitality Private Equity Mergers and Acquisitions Medical 52

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

Certain headwinds and other complicating factors, however, may have tamped down M&A activity in 2021, including: Antitrust regulators continuing to produce uncertainty, with the Federal Trade Commission announcing a number of key policy changes – the full impact of these policy changes on transactions remains to be seen.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40